Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp WT (NQ: LEXXW )

0.7484 UNCHANGED
Streaming Delayed Price Updated: 10:17 AM EST, Nov 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp WT

< Previous 1 2 3 4 5 6 7 Next >
Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs
DehydraTECH™ improves delivery into bloodstream of orally administered remdesivir and ebastine in study VIRAL-A20-2 KELOWNA, BC / ACCESSWIRE / June 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Lexaria Provides Progress Report on Six R&D Programs
- All studies are using DehydraTECH™ 2.0 formulations for multiple market applications, including antivirals, hypertension, NSAIDs and oral nicotine - These studies are part of Lexaria's 2021 applied... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Animal Testing Intellectual Property
Exposures Animal Testing COVID-19 Intellectual Property
Lexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1
- Dosing Is Complete in First of Three Human Clinical Studies Hoped To Validate Lexaria’s Patented Technology for Hypertension Relief - Study Tested an Advanced “DehydraTECH™ 2.0” CBD Formulation -... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Lexaria's DehydraTECH(TM)-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 Virus
KELOWNA, BC / ACCESSWIRE / June 3, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Lexaria's Newest DehydraTECH(TM) 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results Ever
- New formulation delivers up to 2,708% more CBD into bloodstream* - Human clinical hypertension study HYPER-H21-1 also progressing KELOWNA, BC / ACCESSWIRE / May 20, 2021 / Lexaria Bioscience Corp.... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Animal Testing Intellectual Property
Exposures Animal Testing Intellectual Property
Lexaria Strengthens Its International Patent Portfolio to 19 Patents Granted
- New patent granted in India bolsters worldwide patent coverage, adding to existing patents in the EU, the U.S., and Australia KELOWNA, BC / ACCESSWIRE / May 12, 2021 / Lexaria Bioscience Corp.... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria to Present at the Benzinga Global Small Cap Conference on May 13, 2021 at 3:50 p.m. ET
Lexaria Recently Announced Favorable Data on Its First Animal Study, As Well as the Commencement of Its First Human Clinical Study, Under Its 2021 Hypertension R&D Program KELOWNA, BC / ACCESSWIRE /... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Issues Successful Results from First 2021 Study, HYPER-A21-1
- Up to 2,178% more CBD delivered into bloodstream* - Up to 1,737% more CBD delivered into brain tissue* KELOWNA, BC / ACCESSWIRE / May 6, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW)... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Commences Human Clinical Hypertension Study
- Study to examine DehydraTECHTM CBD's ability to control blood pressure - First of three human clinical studies hoped to validate Lexaria's patented technology for hypertension relief KELOWNA, BC /... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Lexaria Appoints New Chief Financial Officer and Issues Consultant Warrants
KELOWNA, BC / ACCESSWIRE / April 15, 2021 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces the... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria's DehydraTECHTM Technology Utilized in Amari's "Everyday Calm," Named a Top CBD Product Pick by New Hope Network
- DehydraTECHTM Powers Amari's Award-Winning Products KELOWNA, BC / ACCESSWIRE / April 14, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property Supply Chain
Exposures Intellectual Property Supply Chain
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.